CORRECTION iCAD Advances Fight Against Breast Cancer with FDA-cleared, Next-Generation AI Solutions and ProFound Health Partnership with Cascaid Health at RSNA 2024
| ICAD Stock | USD 1.97 0.08 4.23% |
About 55% of Icad's shareholders are presently thinking to get in. The analysis of the overall investor sentiment regarding icad inc suggests that some traders are interested. The current market sentiment, together with Icad's historical and current headlines, can help investors time the market. In addition, many technical investors use icad inc stock news signals to limit their universe of possible portfolio assets.
Icad |
ProFound Health, a Virtual Care Partnership with Cascaid Health, to Democratize Access to AI-Powered Mammography for All Patients Launching Q1 2025...
Read at globenewswire.com
 |
Icad Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Icad can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Icad Fundamental Analysis
We analyze Icad's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Icad using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Icad based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Price To Earning
Price To Earning Comparative Analysis
Icad is currently under evaluation in price to earning category among its peers. Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.
icad inc Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Icad stock to make a market-neutral strategy. Peer analysis of Icad could also be used in its relative valuation, which is a method of valuing Icad by comparing valuation metrics with similar companies.
Peers
Icad Related Equities
| BMRA | Biomerica | 7.14 | ||||
| AIMD | Ainos | 6.82 | ||||
| MOVE | Movano | 1.86 | ||||
| SSKN | STRATA Skin | 1.65 | ||||
| LNSR | LENSAR | 0.92 | ||||
| SRDX | SurModics | 0.03 | ||||
| CVRX | CVRx | 1.54 | ||||
| PROF | Profound Medical | 1.59 | ||||
| SIBN | Si Bone | 1.59 | ||||
| ESTA | Establishment Labs | 1.74 | ||||
| FNA | Paragon 28 | 2.01 | ||||
| NVRO | Nevro Corp | 2.09 | ||||
| AXGN | Axogen | 3.03 | ||||
| NVNO | EnVVeno Medical | 3.41 | ||||
| SGHT | Sight Sciences | 4.62 |
Complementary Tools for Icad Stock analysis
When running Icad's price analysis, check to measure Icad's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Icad is operating at the current time. Most of Icad's value examination focuses on studying past and present price action to predict the probability of Icad's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Icad's price. Additionally, you may evaluate how the addition of Icad to your portfolios can decrease your overall portfolio volatility.
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets |